Literature DB >> 2492250

Free radical formation by antitumor quinones.

G Powis1.   

Abstract

Quinones are among the most frequently used drugs to treat human cancer. All of the antitumor quinones can undergo reversible enzymatic reduction and oxidation, and form semiquinone and oxygen radicals. For several antitumor quinones enzymatic reduction also leads to formation of alkylating species but whether this involves reduction to the semiquinone or the hydroquinone is not always clear. The antitumor activity of quinones is frequently linked to DNA damage caused by alkylating species or oxygen radicals. Some other effects of the antitumor quinones, such as cardiotoxicity and skin toxicity, may also be related to oxygen radical formation. The evidence for a relationship between radical formation and the biological activity of the antitumor quinones is evaluated.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2492250     DOI: 10.1016/0891-5849(89)90162-7

Source DB:  PubMed          Journal:  Free Radic Biol Med        ISSN: 0891-5849            Impact factor:   7.376


  59 in total

Review 1.  Macrocyclic inhibitors of hsp90.

Authors:  Victoria A Johnson; Erinprit K Singh; Lidia A Nazarova; Leslie D Alexander; Shelli R McAlpine
Journal:  Curr Top Med Chem       Date:  2010       Impact factor: 3.295

2.  A digitized-fluorescence-imaging study of mitochondrial Ca2+ increase by doxorubicin in cardiac myocytes.

Authors:  E Chacon; R Ulrich; D Acosta
Journal:  Biochem J       Date:  1992-02-01       Impact factor: 3.857

3.  Chemical genetics analysis of an aniline mustard anticancer agent reveals complex I of the electron transport chain as a target.

Authors:  Bogdan I Fedeles; Angela Y Zhu; Kellie S Young; Shawn M Hillier; Kyle D Proffitt; John M Essigmann; Robert G Croy
Journal:  J Biol Chem       Date:  2011-08-10       Impact factor: 5.157

4.  Paradoxical inhibition of cardiac lipid peroxidation in cancer patients treated with doxorubicin. Pharmacologic and molecular reappraisal of anthracycline cardiotoxicity.

Authors:  G Minotti; C Mancuso; A Frustaci; A Mordente; S A Santini; A M Calafiore; G Liberi; N Gentiloni
Journal:  J Clin Invest       Date:  1996-08-01       Impact factor: 14.808

5.  Payload drug vs. nanocarrier biodegradation by myeloperoxidase- and peroxynitrite-mediated oxidations: pharmacokinetic implications.

Authors:  Wanji Seo; Alexandr A Kapralov; Galina V Shurin; Michael R Shurin; Valerian E Kagan; Alexander Star
Journal:  Nanoscale       Date:  2015-05-21       Impact factor: 7.790

6.  Analysis of the activities of RAD54, a SWI2/SNF2 protein, using a specific small-molecule inhibitor.

Authors:  Julianna S Deakyne; Fei Huang; Joseph Negri; Nicola Tolliday; Simon Cocklin; Alexander V Mazin
Journal:  J Biol Chem       Date:  2013-09-16       Impact factor: 5.157

7.  One- and two-electron reduction of 2-methyl-1,4-naphthoquinone bioreductive alkylating agents: kinetic studies, free-radical production, thiol oxidation and DNA-strand-break formation.

Authors:  C Giulivi; E Cadenas
Journal:  Biochem J       Date:  1994-07-01       Impact factor: 3.857

8.  Secondary alcohol metabolites mediate iron delocalization in cytosolic fractions of myocardial biopsies exposed to anticancer anthracyclines. Novel linkage between anthracycline metabolism and iron-induced cardiotoxicity.

Authors:  G Minotti; A F Cavaliere; A Mordente; M Rossi; R Schiavello; R Zamparelli; G Possati
Journal:  J Clin Invest       Date:  1995-04       Impact factor: 14.808

9.  Myricetin protects cells against oxidative stress-induced apoptosis via regulation of PI3K/Akt and MAPK signaling pathways.

Authors:  Kyoung Ah Kang; Zhi Hong Wang; Rui Zhang; Mei Jing Piao; Ki Cheon Kim; Sam Sik Kang; Young Woo Kim; Jongsung Lee; Deokhoon Park; Jin Won Hyun
Journal:  Int J Mol Sci       Date:  2010-11-02       Impact factor: 5.923

10.  Protective effect of melatonin against mitomycin C-induced genotoxic damage in peripheral blood of rats.

Authors:  S Ortega-Gutiérrez; M López-Vicente; F Lostalé; L Fuentes-Broto; E Martínez-Ballarín; J J García
Journal:  J Biomed Biotechnol       Date:  2009-10-20
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.